Acta Diabetologica

, Volume 55, Issue 4, pp 369–375 | Cite as

Bisphenol A is not associated with a 5-year incidence of type 2 diabetes: a prospective nested case–control study

  • Xiaoyu Shu
  • Siying Tang
  • Chuan Peng
  • Rufei Gao
  • Shumin Yang
  • Ting Luo
  • Qingfeng Cheng
  • Yue Wang
  • Zhihong Wang
  • Qianna Zhen
  • Jinbo HuEmail author
  • Qifu LiEmail author
Original Article



The relationship between bisphenol A (BPA) and diabetes remains controversial. This study aims to investigate whether serum BPA level could predict the 5-year incidence of type 2 diabetes (T2D).


A nested case–control study was performed among Chinese who participated in the environment, inflammation and metabolic diseases study (2008–2013). Of the 3510 subjects who were free of diabetes, 232 subjects developed diabetes during the 5-year follow-up. Cases and controls were matched for age and gender by a ratio of 1:1. Homoeostasis model assessment was used to estimate basal β-cell function (HOMA-β) and insulin resistance (HOMA-IR). Participants were stratified into tertiles based on low, median and high baseline serum BPA levels. Regression models were used to analyze the relationship between serum BPA concentration and the incidence of T2D.


At baseline, no significant difference in serum BPA concentration was observed between patients with T2D and controls [1.3 (0.3, 3.7) vs. 1.6 (0.4, 3.9) μmol/L, P = 0.199]; serum BPA concentration was positively associated with fasting plasma glucose (r = 0.27, P < 0.001); however, neither HOMA-β nor HOMA-IR correlated with serum BPA concentration. During the follow-up, baseline BPA levels could not predict the 5-year T2D incidence, whether or not adjusted for the potential confounders such as body mass index and blood pressure. [Low BPA tertile was the reference, OR 0.66 (95% CI 0.30, 1.44) for median, OR 0.93 (95% CI 0.41, 2.13) for high.]


BPA is not associated with a 5-year T2D incidence. These data do not support previous cross-sectional study that BPA exerted a detrimental effect on glucose metabolism.


Bisphenol A Type 2 diabetes Risk Prospective study 



The authors thank Laboratory of Endocrine and the Laboratory of Lipid & Glucose Metabolism, the First Affiliated Hospital of Chongqing Medical University.

Author Contributions

Xiaoyu Shu and Siying Tang designed the study, oversaw the data collection and wrote the manuscript. Chuan Peng and Rufei Gao conducted the data analysis and contributed to the writing of the manuscript. Shumin Yang, Ting Luo and Yue Wang contributed to the study design and provided statistical expertise. Qingfeng Cheng contributed to the writing of the manuscript. Zhihong Wang assisted with the data collection and contributed to the writing and editing of the manuscript. Qianna Zhen contributed to the writing of the manuscript. Jinbo Hu and Qifu Li are the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.


National key research & development plan, major project of precision medicine research (2017YFC0909600, sub-project: 2017YFC0909602, 2017YFC0909603). National Key Clinical Specialties Construction Program of China to the Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University; and the National Natural Science Foundation of China (81370954, 81670785) to Qifu Li; and the Fundamental Science & Advanced Technology Research of Chongqing (Major Project, cstc2015jcyjBX0096) to Qifu Li. Chongqing Science and Technology Committee Innovation Project (Technology Development and Application of Precision Medicine, cstc2016shms-ztzx1003) to Qifu Li.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Human and animal rights

All human studies have been reviewed by the committee and have been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki.

Informed consent

All participants gave their informed consent prior to their inclusion in the study.


  1. 1.
    Menke A, Casagrande S, Geiss L, Cowie CC (2015) Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA 314:1021–1029CrossRefPubMedGoogle Scholar
  2. 2.
    Wang L, Gao P, Zhang M, Huang Z, Zhang D, Deng Q et al (2017) Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA 317:2515–2523CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Xu Y, Wang L, He J, Bi Y, Li M, Wang T et al (2013) Prevalence and control of diabetes in Chinese adults. JAMA 310:948–959CrossRefPubMedGoogle Scholar
  4. 4.
    Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J et al (2010) Prevalence of diabetes among men and women in China. N Engl J Med 362:1090–1101CrossRefPubMedGoogle Scholar
  5. 5.
    Ruiz D, Becerra M, Jagai JS, Ard K, Sargis RM (2018) Disparities in environmental exposures to endocrine-disrupting chemicals and diabetes risk in vulnerable populations. Diabetes Care 41:193–205CrossRefPubMedGoogle Scholar
  6. 6.
    Song Y, Chou EL, Baecker A, You NC, Song Y, Sun Q et al (2016) Endocrine-disrupting chemicals, risk of type 2 diabetes, and diabetes-related metabolic traits: a systematic review and meta-analysis. J Diabetes 8:516–532CrossRefPubMedGoogle Scholar
  7. 7.
    Vandenberg LN, Maffini MV, Sonnenschein C, Rubin BS, Soto AM (2009) Bisphenol-A and the great divide: a review of controversies in the field of endocrine disruption. Endocr Rev 30:75–95CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Song Y, Hauser R, Hu FB, Franke AA, Liu S, Sun Q (2014) Urinary concentrations of bisphenol A and phthalate metabolites and weight change: a prospective investigation in US women. Int J Obes (Lond) 38:1532–1537CrossRefGoogle Scholar
  9. 9.
    Melzer D, Osborne NJ, Henley WE, Cipelli R, Young A, Money C et al (2012) Urinary bisphenol A concentration and risk of future coronary artery disease in apparently healthy men and women. Circulation 125:1482–1490CrossRefPubMedGoogle Scholar
  10. 10.
    Bae S, Hong YC (2015) Exposure to bisphenol A from drinking canned beverages increases blood pressure: randomized crossover trial. Hypertension 65:313–319CrossRefPubMedGoogle Scholar
  11. 11.
    Moon MK, Jeong IK, Oh TJ, Ahn HY, Kim HH, Park YJ et al (2015) Long-term oral exposure to bisphenol A induces glucose intolerance and insulin resistance. J Endocrinol 226:35–42CrossRefPubMedGoogle Scholar
  12. 12.
    Jayashree S, Indumathi D, Akilavalli N, Sathish S, Selvaraj J, Balasubramanian K (2013) Effect of bisphenol-A on insulin signal transduction and glucose oxidation in liver of adult male albino rat. Environ Toxicol Pharmacol 35:300–310CrossRefPubMedGoogle Scholar
  13. 13.
    Lin Y, Sun X, Qiu L, Wei J, Huang Q, Fang C et al (2013) Exposure to bisphenol A induces dysfunction of insulin secretion and apoptosis through the damage of mitochondria in rat insulinoma (INS-1) cells. Cell Death Dis 4:e460CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Lang IA, Galloway TS, Scarlett A, Henley WE, Depledge M, Wallace RB et al (2008) Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA 300:1303–1310CrossRefPubMedGoogle Scholar
  15. 15.
    Aekplakorn W, Chailurkit LO, Ongphiphadhanakul B (2015) Relationship of serum bisphenol A with diabetes in the Thai population, National Health Examination Survey IV, 2009. J Diabetes 7:240–249CrossRefPubMedGoogle Scholar
  16. 16.
    Sun Q, Cornelis MC, Townsend MK, Tobias DK, Eliassen AH, Franke AA et al (2014) Association of urinary concentrations of bisphenol A and phthalate metabolites with risk of type 2 diabetes: a prospective investigation in the Nurses’ health study (NHS) and NHSII cohorts. Environ Health Perspect 122:616–623CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Hu J, Yang S, Wang Y, Goswami R, Peng C, Gao R et al (2015) Serum bisphenol A and progression of type 2 diabetic nephropathy: a 6-year prospective study. Acta Diabetol 52:1135–1141CrossRefPubMedGoogle Scholar
  18. 18.
    Hu J, Wang Y, Xiang X, Peng C, Gao R, Goswami R et al (2016) Serum bisphenol A as a predictor of chronic kidney disease progression in primary hypertension: a 6-year prospective study. J Hypertens 34:332–337CrossRefPubMedGoogle Scholar
  19. 19.
    Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D et al (2008) Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 371:1753–1760CrossRefPubMedGoogle Scholar
  20. 20.
    Shankar A, Teppala S (2011) Relationship between urinary bisphenol A levels and diabetes mellitus. J Clin Endocrinol Metab 96:3822–3826CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Bi Y, Wang W, Xu M, Wang T, Lu J, Xu Y et al (2016) Diabetes genetic risk score modifies effect of bisphenol A exposure on deterioration in glucose metabolism. J Clin Endocrinol Metab 101:143–150CrossRefPubMedGoogle Scholar
  22. 22.
    Stojanoska MM, Milosevic N, Milic N, Abenavoli L (2017) The influence of phthalates and bisphenol A on the obesity development and glucose metabolism disorders. Endocrine 55:666–681CrossRefPubMedGoogle Scholar
  23. 23.
    Alonso-Magdalena P, Morimoto S, Ripoll C, Fuentes E, Nadal A (2006) The estrogenic effect of bisphenol A disrupts pancreatic beta-cell function in vivo and induces insulin resistance. Environ Health Perspect 114:106–112CrossRefPubMedGoogle Scholar
  24. 24.
    Wang X, Wang X, Chen Q, Luo ZC, Zhao S, Wang W et al (2017) Urinary bisphenol A concentration and gestational diabetes mellitus in Chinese women. Epidemiology 28(Suppl 1):S41–S47CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of EndocrinologyThe First Affiliated Hospital of Chongqing Medical UniversityChongqingChina
  2. 2.Department of EndocrinologyThe Affiliated Hospital of Guizhou Medical UniversityGuiyangChina

Personalised recommendations